Moderator: Michael G. Fehlings, MD, PhD, FRCSC
215. Outcomes of decompression without fusion in patients with lumbar spinal stenosis with back pain
Rachid Bech-Azeddine, MD, PhD1; Soren Fruensgaard, MD2; Mikkel Andersen, MD3; Leah Y. Carreon, MD, MSc4,5 ; Simon T. Sorensen, MS6
1Bagsvaerd, Denmark; 2Silkeborg Central Hospital, Silkeborg, Denmark; 3Middelfart, Denmark; 4Sygehus Lillebælt - Rygkirurgi Middelfart, Middelfart, Middelfart, Denmark; 5Norton Leatherman Spine Center, Louisville, KY, US; 6Center for Spine Surgery & Research, Middelfart Hospital
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
216. Ambulatory status after surgical and nonsurgical treatment for spinal metastasis
Andrew J. Schoenfeld, MD1; Elena Losina2; Marco Ferrone, MD1; Joseph H. Schwab, MD3; Justin A. Blucher, MS1; Genevieve S. Silva, BS1; Angela T. Chen, BS, MA1; Mitchel Harris, MD, FACS3; James D. Kang, MD1; Jeffrey Katz, MD, MS1
1Brigham and Women's Hospital, Boston, MA, US; 2Boston, MA, US; 3Massachusetts General Hospital, Boston, MA, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
217. Impact of previous lumbar spine surgery on outcome of lumbar total disc replacement: analysis of prospective five-year follow up study data
Richard D. Guyer, MD1; Scott L. Blumenthal, MD2; Jack E. Zigler, MD2; Donna D. Ohnmeiss, PhD3
1Center for Disc Replacement at Texas Back Institute, Plano, TX, US; 2Texas Back Institute, Plano, TX, US; 3Plano, TX, US
FDA Device/Drug Status: activL (Approved for this indication), ProDisc-L (Approved for this indication), Charite (Approved for this indication)
218. Randomized, prospective clinical trial to evaluate efficacy and safety in lumbar fusion surgery of implantation of autologous bone marrow mesenchymal cells expanded ex vivo and combined with allogeneic bone tissue, compared with autologous iliac crest graft: part I: radiological findings
Pilar Gonzalez-Tartiere, MSc1; Ana García de Frutos, MD2; Maite T. Ubierna, MD3; Alejandro Del Arco, MD4; Guillem Salo, MD, PhD5; Antonia Matamalas, MD6; Ruth Coll, PhD7; Nuria Ribo, MSc7; Joan García, PhD7; Antoni Rivas, MD, PhD2; Juan Bagó, MD, PhD2; Enric Caceres, MD, PhD8; Juan José Velázquez, MD9
1Vall d'Hebron Research Institute (VHIR), Barcelona, Spain; 2Hospital Vall d'Hebron, Barcelona, Barcelona, Spain; 3German Trias I Pujol, Barcelona, Spain; 4Hospital del Mar, Barcelona, Barcelona, Spain; 5Hospital del Mar, Santpedor, Spain; 6Barcelona, Spain; 7Banc de Sang i Teixits BST, Barcelona, Barcelona, Spain; 8Hospital Universitari Dexeus, Barcelona, Barcelona, Spain; 9Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
FDA Device/Drug Status: XCEL-MT-OSTEO-ALPHA (Not approved for this indication)
219. Evaluation of health related quality of life improvement in patients undergoing spine versus adult reconstructive surgery
Christopher Varlotta, BS1; Dennis Vasquez-Montes, MS, BA1; Jordan H. Manning, BA1; Erik Wang, BA1; Edem J. Abotsi, BA1; Mohamed A. Moawad, MPH1; John A. Bendo, MD2; Charla R. Fischer, MD3; James Slover, MD2; Ran Schwarzkopf, MD4; Jonathan M. Vigdorchik, MD4; Joseph Zuckerman, MD3; Aaron J. Buckland, MBBS, FRACS1
1Department of Orthopedic Surgery, NYU Langone Orthopedic Hospital, NYU Langone Health, New York, NY, US; 2NYU Langone Orthopedic Hospital, New York, NY, US; 3New York, NY, US; 3Hospital for Joint Diseases at NYU Langone Medical Center, New York, NY, US>
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
2019 Value Award Winner
220. Are current DRG-based bundled payment models for lumbar fusions risk-adjusting adequately? an analysis of medicare beneficaries
Azeem T. Malik, MBBS1; Frank M. Phillips, MD2; Elizabeth Yu, MD1; Safdar N. Khan, MD1
1The Ohio State University Wexner Medical Center, Columbus, OH, US; 2Midwest Orthopaedics At Rush, Chicago, IL, US
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
221. Intravenous and oral tranexamic acid are equivalent at reducing blood loss in thoracolumbar spinal fusion: a prospective randomized trial phase II
Charles C. Yu, MD1; Mohsin S. Fidai, MD1; Omar Kadri, MD2; Allen A. Kadado, MD3; Stephen Bartol, MD, MBA, FRCSC4
1Henry Ford Health System, Detroit, MI, US; 2Henry Ford Hospital, Detroit, MI, US; 3Detroit, MI, US; 4Windsor, ON, Canada>
FDA Device/Drug Status: This abstract does not discuss or include any applicable devices or drugs.
Discussion